Legacy Novozymes delivers solid last full-year results
01 Février 2024 - 8:00AM
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes is delivering solid growth and earnings in a
year characterized by changing market demands, with 6% organic
sales growth in Q4 and 5% organic sales growth in 2023. This marks
the last financial reporting from legacy Novozymes, and the new
company, Novonesis, is already a reality.
COPENHAGEN, Denmark – February 1, 2024. In the 2023
financial year, legacy Novozymes delivers 5% organic sales growth –
6% organic sales growth in the fourth quarter alone – an
EBIT-margin before special items[*] of 25.4%, and ROIC including
goodwill before special items* of 16.5%. As Novozymes just closed
the combination with Chr. Hansen on January 29, and the annual
report now is expected to be released on February 8, this
announcement only contains selected unaudited numbers. Full audited
financial statements as well as non-financial numbers will be
released with the annual report on February 8. Novonesis will
present a 2024 financial outlook no later than March 31.
“Legacy Novozymes has leveraged its strengths of a
well-diversified portfolio, unique production capabilities, and
broad market presence to deliver strong growth in a volatile
market. Biosolutions hold the key to some of the world’s biggest
challenges, and the growth in 2023 confirms the continued
trajectory to growth as well as demand and strong momentum, says
Ester Baiget, President & CEO, and continues:
“Now, we start a new chapter as Novonesis. The combination
between two great companies is now a reality, and we are set to
further accelerate growth and to develop transformative
biosolutions as the leading global biosolutions partner. We have
gathered the brightest minds, and together with my more than 10,000
colleagues, we will unlock the limitless potential of biosolutions.
A special thank you to all our stakeholders for your support. We
are ready to lead the new era of biosolutions.”
In the 2023 financial year, legacy Novozymes launched 18 new
biosolutions to meet customer needs, seven of which were
public.
Growth rates across business areas For the full year,
organic performance by business area was 5% in Household Care, -2%
in Food, Beverages & Human Health, 23% in Bioenergy, -6% in
Grain & Tech Processing, and 3% in Agriculture, Animal Health
& Nutrition.
Performance in Food, Beverages & Human Health was impacted
by destocking and a tough year-on-year comparator. Grain & Tech
Processing was affected by an expected reduction in sales to
Covid-19 test kits and declining textile market demand.
Strong growth across both developed and emerging markets
Legacy Novozymes sales grew 5% in 2023 organically compared to the
previous year with 6% growth in developed markets and 4% growth
emerging markets.
Bioenergy was the main driver of growth in developed markets
with contributions from Agriculture, Animal Health & Nutrition
and Household Care despite declining industry volumes.
Growth in emerging markets was driven by Bioenergy and with
contributions from Household Care.
For 2023, organic growth rates by geography were 3% in Europe,
Middle East & Africa, 7% in North America, -1% in Asia Pacific,
and 17% in Latin America.
|
|
|
Media
Relations |
|
|
Lina Danstrup
Head of External Communications Phone: +45 30 77 05 52
anse@novozymes.com |
|
|
|
|
|
Investor
Relations |
|
|
Tobias Cornelius
Björklund Head of Investor Relations Phone: +45 30 77 86 82
tobb@novozymes.com |
|
|
[*] Special items include costs related to the combination with
Chr. Hansen
- Novozymes FY_2023_Press Release
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Novonesis AS (TG:NZM2)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024